Advances in patient care through increasingly individualized therapy
Advances in patient care through increasingly individualized therapy, Published online: 02 January 2019; doi:10.1038/s41571-018-0156-2In 2018, the acute myeloid leukaemia treatment landscape expanded notably, with several trials leading to the approval of novel targeted therapies. Furthermore, comprehensive sequencing revealed the effects of co-occurring mutations and gene expression patterns on drug sensitivity, providing hope that future treatments will be increasingly precise and personalized. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 2, 2019 Category: Cancer & Oncology Authors: Courtney D. DiNardo Alexander E. Perl Source Type: research
Alliance to iLLUMINATE the chemo-free sign
Alliance to iLLUMINATE the chemo-free sign, Published online: 21 December 2018; doi:10.1038/s41571-018-0158-0Alliance to iLLUMINATE the chemo-free sign (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 21, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Two steps forward and one step back
Two steps forward and one step back, Published online: 21 December 2018; doi:10.1038/s41571-018-0154-4Perioperative chemotherapy is the standard of care for localized gastric cancer (GC). In 2018, additional postoperative radiotherapy was found to be ineffective; although, docetaxel was found to be superior to epirubicin in perioperative three-drug chemotherapy regimens. Validated biomarkers are needed for benefit from immunotherapy in advanced-stage GC. Metachronous GC can be prevented by Helicobacter pylori eradication. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 21, 2018 Category: Cancer & Oncology Authors: Florian Lordick Elizabeth C. Smyth Source Type: research
TIL infusions effective in HPV-associated cancers
TIL infusions effective in HPV-associated cancers, Published online: 20 December 2018; doi:10.1038/s41571-018-0160-6TIL infusions effective in HPV-associated cancers (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Apixaban reduces risk of thromboembolism
Apixaban reduces risk of thromboembolism, Published online: 20 December 2018; doi:10.1038/s41571-018-0162-4Apixaban reduces risk of thromboembolism (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Myeloid immune-checkpoint inhibition enters the clinical stage
Myeloid immune-checkpoint inhibition enters the clinical stage, Published online: 20 December 2018; doi:10.1038/s41571-018-0155-3The first-in-human study of anti-CD47 antibodies blocking CD47–SIRPα interactions in combination with rituximab in patients with non-Hodgkin lymphoma shows encouraging clinical responses accompanied with mild levels of toxicity. Inhibition of the CD47–SIRPα interaction might provide a generic method of promoting the effects of antitumour antibodies in a variety of cancer types. This reveals, for the first time, an innate immune checkpoint as a bona fide target for therapy. (Source: Nature C...
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Timo K. van den Berg Thomas Valerius Source Type: research
Setting dictates efficacy of pembrolizumab in TNBC
Setting dictates efficacy of pembrolizumab in TNBC, Published online: 20 December 2018; doi:10.1038/s41571-018-0157-1Setting dictates efficacy of pembrolizumab in TNBC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Relapsed glioblastomas respond to regorafenib
Relapsed glioblastomas respond to regorafenib, Published online: 20 December 2018; doi:10.1038/s41571-018-0161-5Relapsed glioblastomas respond to regorafenib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
MRD to help assess response in CLL
MRD to help assess response in CLL, Published online: 20 December 2018; doi:10.1038/s41571-018-0159-zMRD to help assess response in CLL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 20, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Advances in prediction for ovarian cancer treatment stratification
Advances in prediction for ovarian cancer treatment stratification, Published online: 19 December 2018; doi:10.1038/s41571-018-0147-3Breakthrough findings reported in 2018 provide the foundations for paradigm shifts in the care of patients with ovarian cancer. These results have implications for treatment in the first-line setting (with improved and refined use of established treatment modalities), firmly introduce concepts of consolidation and maintenance therapy, and enable more accurate prediction of drug sensitivity and resistance. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2018 Category: Cancer & Oncology Authors: Amit M. Oza Source Type: research
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer
Beyond 5 years: enduring risk of recurrence in oestrogen receptor-positive breast cancer, Published online: 18 December 2018; doi:10.1038/s41571-018-0145-5Women with early-stage oestrogen receptor (ER)-positive (ER+) breast cancer remain at risk of distant recurrence for at least 15 years after discontinuation of 5 years of standard endocrine therapy. The authors of this Review discuss the epidemiology and mechanisms underlying late recurrence and examine several models used for risk prognostication and for estimating the presence of minimal residual disease. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Juliet Richman Mitch Dowsett Source Type: research
New high-risk molecular subtypes of DLBCL identified
New high-risk molecular subtypes of DLBCL identified, Published online: 18 December 2018; doi:10.1038/s41571-018-0153-5New high-risk molecular subtypes of DLBCL identified (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 18, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Physician burnout: let’s avoid unsubstantiated claims
Physician burnout: let’s avoid unsubstantiated claims, Published online: 18 December 2018; doi:10.1038/s41571-018-0150-8Physician burnout: let’s avoid unsubstantiated claims (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Danijela Mirkovic Renzo Bianchi Source Type: research
mCRC: sequencing in REVERCE
mCRC: sequencing in REVERCE, Published online: 18 December 2018; doi:10.1038/s41571-018-0152-6mCRC: sequencing in REVERCE (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 18, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Reply to ‘Physician burnout: let’s avoid unsubstantiated claims’
Reply to ‘Physician burnout: let’s avoid unsubstantiated claims’, Published online: 18 December 2018; doi:10.1038/s41571-018-0151-7Reply to ‘Physician burnout: let’s avoid unsubstantiated claims’ (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 18, 2018 Category: Cancer & Oncology Authors: Susana Banerjee Source Type: research
